| Identification | Back Directory | [Name]
GQ-16 | [CAS]
870554-67-9 | [Synonyms]
GQ-16
GQ-16 Exclusive
5Z-[(5-bromo-2-methoxyphenyl)methylene]-3-[(4-methylphenyl)methyl]-2,4-thiazolidinedione
(5Z)-5-[(5-bromo-2-methoxyphenyl)methylidene]-3-[(4-methylphenyl)methyl]-1,3-thiazolidine-2,4-dione | [Molecular Formula]
C19H16BrNO3S | [MOL File]
870554-67-9.mol | [Molecular Weight]
418.3 |
| Chemical Properties | Back Directory | [Melting point ]
147 °C | [Boiling point ]
549.8±60.0 °C(Predicted) | [density ]
1.522±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≤0.33mg/ml in DMSO;5mg/ml in dimethyl formamide | [form ]
crystalline solid | [pka]
-2.57±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
Full activation of peroxisome proliferator-activated receptor γ (PPARγ), e.g., using thiazolidinediones, effectively treats insulin resistance and type 2 diabetes but also commonly promotes weight gain, hyperphagia, and edema. GQ-16 is a partial agonist for PPARγ (Ki = 160 nM) which induces adipogenesis significantly less than the full activator rosiglitazone. Like rosiglitazone, GQ-16 reverses high fat diet-mediated impairments in insulin signaling. However, GQ-16 does not induce weight gain, hyperphagia, or edema. GQ-16 does not activate PPARα, PPARβ/δ, or RXRα. | [Uses]
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a Ki of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain[1]. | [in vitro]
gq-16 was an effective inhibitor of cdk5-mediated phosphorylation of pparγ, exhibiting a ki value of 160 nm. gq-16 was specific for pparγ and possessed no detectable activity when tested for the ability to activate other ppar subtypes (pparα or pparβ/δ) or rxrα. in both nih-3t3 and c3h10t1/2 cell models with established pparγ-dependent adipogenesis, gq-16 displayed reduced the potential of adipogenic [1]. | [in vivo]
in the mouse model of diet-induced obesity and insulin resistance, administration of gq-16 (20 mg/kg/day) by oral gavage daily blocked hfd-dependent effects on intracellular inflammatory pathways and improved insulin sensitivity. gq-16 did not elicit increased weight gain [1]. | [References]
[1] amato a a, rajagopalan s, lin j z, et al. gq-16, a novel peroxisome proliferator-activated receptor γ (pparγ) ligand, promotes insulin sensitization without weight gain[j]. journal of biological chemistry, 2012, 287(33): 28169-28179. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|